Acura Pharmaceuticals IncFind Ratings Reports
ACURA PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company has grown sales and net income during the past quarter when compared with the same quarter a year ago, however, it was unable to keep up with the growth of the average competitor within its industry. ACURA PHARMACEUTICALS INC has average liquidity. Currently, the Quick Ratio is 1.06 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 105.60% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY16||Q3 FY15|
|Net Sales ($mil)||0.22||0.21|
|Net Income ($mil)||-2.25||-2.65|
|Balance Sheet||Q3 FY16||Q3 FY15|
|Cash & Equiv. ($mil)||4.27||15.25|
|Total Assets ($mil)||7.74||18.94|
|Total Debt ($mil)||6.19||8.51|
|Profitability||Q3 FY16||Q3 FY15|
|Gross Profit Margin||91.28||64.76|
|Return on Assets||-127.13||-35.73|
|Return on Equity||0.0||-77.58|
|Debt||Q3 FY16||Q3 FY15|
|Share Data||Q3 FY16||Q3 FY15|
|Shares outstanding (mil)||11.83||11.8|
|Div / share||0.0||0.0|
|Book value / share||-0.04||0.74|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||544451.0||47644.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ACUR NM||Peers 46.08||ACUR NM||Peers 21.15|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ACUR's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ACUR's P/CF is negative making the measure meaningless.
|ACUR NM||Peers 15.57||ACUR NA||Peers 0.55|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ACUR's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ACUR NM||Peers 18.85||ACUR -31.74||Peers 4.06|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ACUR's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ACUR is expected to significantly trail its peers on the basis of its earnings growth rate.
|ACUR 3.12||Peers 13.85||ACUR -42.49||Peers 3.91|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ACUR is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ACUR significantly trails its peers on the basis of sales growth